Greggs Shares Near 5-Year Lows Amid Economic Headwinds, GLP-1 Concerns

Executive Summary

Greggs shares have plummeted to near 5-year lows since 2025, becoming one of the FTSE 250's worst performers due to weak consumer confidence, rising costs, and over-expansion. This decline reflects broader UK economic pressures and introduces a new structural threat from weight-loss drugs impacting bakery sales, challenging traditional growth models. Monitor Greggs' menu adaptation, the trajectory of GLP-1 drug adoption, and overall consumer spending trends to gauge potential recovery or further market revaluation.

Extended Analysis

Greggs' significant share price depreciation since 2025, plummeting from 2,800p to 1,600p, underscores a confluence of macroeconomic headwinds and emerging structural challenges. The initial drivers—weakened consumer confidence, escalating operational costs, and potentially aggressive store expansion into a cooling UK economy—reflect a broader struggle for discretionary retail. While a neutral broker consensus (seven Buy, five Hold, four Sell) suggests a modest 12-month recovery target of 1,700p, this masks a deeper divergence in expert opinion regarding the company's long-term trajectory. Bullish analysts, including JP Morgan and RBC Capital, view Greggs as a 'structural winner' with robust unit economics and strong sales per square foot, anticipating earnings and free cash flow improvements from new stores and enhanced distribution. RBC projects 11% annual organic growth, supported by a seven-year expansion plan. However, these optimistic outlooks are predicated on a sustained improvement in sales and margins, which remains precarious given the current economic climate. The primary counter-narrative centers on persistent consumer demand weakness and a novel, potentially transformative threat: weight-loss drugs (GLP-1s). Jefferies' recent downgrade from Buy to Hold, citing GLP-1s, highlights a significant second-order effect on the food industry. Greggs' CEO, Roisin Currie, acknowledges the impact, noting increased customer demand for smaller portions and healthier options. While Greggs is adapting its menu, the long-term penetration and behavioral shifts induced by GLP-1s could fundamentally alter the quick-service bakery market, challenging established product mixes and sales volumes. For investors, the current low valuation and a 4.3% dividend yield offer some appeal, pricing in a 'slow, grinding comeback.' However, the recovery's pace and magnitude are highly contingent on successful menu adaptation, the broader economic environment, and the uncertain trajectory of GLP-1 adoption. Greggs' situation serves as a microcosm for UK retail, navigating inflation, consumer belt-tightening, and disruptive health trends that necessitate profound strategic agility beyond traditional growth models.

Strategic Impact Assessment

• ◉Greggs' share decline signals broader UK consumer discretionary spending weakness and inflationary pressures.
• ◉Emergence of GLP-1 drugs poses a novel, structural threat to traditional food retail and quick-service restaurant models.
• ◉Broker consensus indicates cautious optimism, but with modest recovery targets, reflecting market uncertainty on growth drivers.
• ◉The company's expansion strategy faces re-evaluation given current economic cooling and changing consumer preferences.